Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-03-21
2008-10-14
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S014800, C514S015800, C530S326000, C530S327000, C530S328000
Reexamination Certificate
active
07435721
ABSTRACT:
The invention relates to peptides derived from or similar to the Ernsprotein of pestiviruses for type-specific diagnosis of infection, for eliciting antibiotic activity, and for transport of substances into a cell. For these purposes, the invention provides, among other things, an isolated, synthetic or recombinant protein or peptide module or functional equivalent thereof comprising an amino acid sequence having significant homology to, for example, an amino acid sequence of a peptide located from about amino acid position (a) 194 to about 220 in a pestiviral Ernsprotein (b) 59 to about 88 in an L3 loop of a cytotoxic RNase of a ribosome-inactivating protein, or (c) 187 to about 223 in a respiratory syncytial virus G-protein.
REFERENCES:
patent: 5877153 (1999-03-01), Harris et al.
patent: 5888762 (1999-03-01), Joliot et al.
patent: 6149911 (2000-11-01), Binz et al.
patent: 6200955 (2001-03-01), Harris et al.
patent: 6261569 (2001-07-01), Comis et al.
patent: 7067487 (2006-06-01), Langedijk
patent: 2005/0027457 (2005-02-01), Mandell et al.
patent: 0 982 402 (2000-03-01), None
patent: WO 95/27787 (1995-10-01), None
patent: WO 95/34308 (1995-12-01), None
patent: WO 97/47312 (1997-12-01), None
patent: WO 97/49726 (1997-12-01), None
patent: WO 99/03987 (1999-01-01), None
patent: WO 99/06569 (1999-02-01), None
patent: WO 00/09701 (2000-02-01), None
patent: WO 02/00882 (2002-01-01), None
Aldrian-Herrada et al. A peptide nucleic acid (PNA) is more rapidly internalized . . . Nucleic Acids Research. 1998, vol. 26, No. 21, pp. 4910-4916).
Chang et al., HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix associated heparan sulfate proteoglycans through its basic region, AIDS, 1997, pp. 142131, vol. 11. No. 12.
Feldman, Steven A., et al., “Identification of a Linear Heparin Binding Domain for Human Respiratory Syncytial Virus Attachment Glycoprotein G,” 73(8) Journal of Virology 661017 (Aug. 1999).
Guichard, Gilles, et al., “Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics,” 91 Proc. Natl. Acad. Sci. USA 9765-69 (Oct. 1994).
International Preliminary Examination Report, International Application No. PCT/NL01/00484, dated Jul. 9, 2002 (3 pages).
International Search Report, International Application No. PCT/NL01/00484, dated Mar. 22, 2002 (7 pages).
Kishore, Ram, et al., “Interaction of the NH2-terminal Domain of Fibronectin with Heparin,” 272(27) The Journal of Biological Chemistry 17078-85 (1997).
Langeduk et al., Enzyme-Linked Immunosorbent Assay Using a Virus, Journal of Clinical Microbiology, Mar. 2001, pp. 906-912, vol. 39, No. 3.
Lindgren et al., Cell-penetrating peptides, Review, Mar. 2000, pp. 99-103, vol. 21.
Mancheno, Jose M., et al., “Predictive Study of the Conformation of the Cytotoxic Protein eSarcin: A Structural Model to Explain α-Sarcin-Membrane Interaction,” 172 J. Theor. Biol. 259-67 (1995).
Mayo, Kevin H., “Recent advances in the design and construction of synthetic peptides: for the love of basics or just for the technology of it,” 18 Tibtech 212-17 (May 2000).
Moormann, R.J.M, “Recent Developments in Pig Vaccinology,” Proceedings of the 14th IPVS Congress, Gologna, Italy, 25-29 (Jul. 7-10, 1996).
Yang, Xiaojing, et al., “Insights into specificity of cleavage and mechanism of cell entry from the crystal structure of the highly specific Aspergillus ribotoxin, restrictocin,” 4(7) Structure 83752 (1996).
Pepscan Systems B.V.
Russel Jeffrey E
TraskBritt
LandOfFree
Transport peptides such as C-terminal E rns peptide and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transport peptides such as C-terminal E rns peptide and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transport peptides such as C-terminal E rns peptide and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3998368